Alaunos Therapeutics completed its acquisition of Velaris Therapeutics alongside an oversubscribed $350 million private placement led by Fairmount, adding a pulmonary arterial hypertension pipeline built around activin-pathway ligand traps and a PDGF-B antibody. Lead candidate VLR199 is designed to reproduce the pharmacology of the approved activin-signaling inhibitor while sparing BMP-9 and BMP-10, the molecules linked to hematologic side effects. No human data have been reported; proof-of-concept results are expected in 2028, with funding projected into 2029.
Key Points
- Alaunos acquires Velaris with $350m placement, runway into 2029
- Lead ligand trap targets activin signaling while sparing BMP-9/BMP-10
- No human data yet; proof-of-concept for VLR199 due 2028
Longevity Analysis
Pressure in the pulmonary arteries sits at the junction of how efficiently blood moves and how effectively oxygen is extracted, and its secondary forms — tied to heart failure with preserved ejection fraction and interstitial lung disease — track closely with functional decline in later decades. Refining activin-pathway inhibition to spare BMP-9 and BMP-10 reflects a broader shift toward intervening on a specific signal rather than suppressing an entire pathway and absorbing the downstream cost. Capital concentration of this scale around a single mechanism signals where remodeling of the pulmonary vasculature is expected to become tractable, though the absence of human data keeps the timeline long.
Original published by Longevity.Technology, by Kyle Umipig.